Science & Biotechnology
GHI specializes in Asymmetrical Gene-Silencing Technology (aiRNA), Novel Nanotechnology DDS, and Synthetic Biology.
Asymmetrical Gene-Silencing Technology (aiRNA)
RNAi (RNA interference) is a revolutionary discovery due to its broad applications for biology and its limitless potential to treat genetic, epigenetic and infectious diseases. RNAi technology can potentially target any disease genes, including conventionally “undruggable” targets. However, the siRNA-based approaches have encountered many challenges including non-specific off-target effects, synthesis cost, and limited efficacy for some genes.
GHI’s proprietary asymmetrical interfering RNA (aiRNA) technology centers on smaller 15 bp asymmetric structures in contrast to the current paradigm that relies primarily on symmetric siRNA duplexes of 19-21 bp in length. Unlike siRNA, aiRNA’s novel asymmetric structure has demonstrated its ability to minimize off-target effects, improve the performance of gene silencing, and reduce the cost of synthesis.
Novel Nanotechnology DDS
Nanotechnology focuses on materials that have dimensions of 1 to 100 nm. The science of nanotechnology extends into almost every discipline, including chemistry, materials science, biology, and medicine.
At 1Globe Health Institute, our scientists are applying nanotechnology principles to develop the next generation of drug delivery vehicles. 1Globe Health Institute scientists research and develop nanoscale vehicles that encapsulate our aiRNA therapeutic, and deliver it to cancerous cells.
Synthetic biology involves the design and construction of biological systems with novel functions. At 1Globe Health Institute, our scientists are using a combination of rational design and genetic engineering to make novel proteins, useful bacteria and modified patient cells that have the ability to prevent and cure life-threatening diseases.